Pharvaris Stock Gets Higher EPS Forecast from HC Wainwright

Key Points

• HC Wainwright raised Pharvaris’ FY2028 EPS estimate to a loss of $0.48 per share from $0.56 previously and maintained a “Buy” rating. The analyst forecast remains more optimistic than the current-year consensus loss estimate of $3.12 per share.
• Analyst sentiment is broadly positive, with 13 Buy, one Hold and one Sell rating, producing a “Moderate Buy” consensus and an average price target of $58.60.
• Insiders sold heavily: company executives sold 513,102 shares worth approximately $18.6 million over the past three months, including significant sales by the president and a director.

Pharvaris N.V. (NASDAQ:PHVS - Free Report) - Equities researchers at HC Wainwright increased their FY2028 EPS estimates for Pharvaris in a research report issued to clients and investors on Tuesday, October 6th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($0.48) for the year, up from their prior estimate of ($0.56). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Pharvaris' current full-year earnings is ($3.12) per share.

A number of other equities analysts have also weighed in on PHVS. Weiss Ratings restated a "sell (d-)" rating on shares of Pharvaris in a research note on Friday, July 17th. Leerink Partners boosted their price objective on Pharvaris from $50.00 to $65.00 and gave the stock an "outperform" rating in a report on Wednesday, September 9th. New Street Research set a $60.00 price objective on shares of Pharvaris in a research report on Friday, August 14th. Wells Fargo & Company raised their target price on shares of Pharvaris from $55.00 to $65.00 and gave the company an "overweight" rating in a research note on Wednesday, September 9th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $65.00 target price on shares of Pharvaris in a research report on Monday, September 14th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $58.60.

Pharvaris Stock Performance

Shares of PHVS stock opened at $31.68 on Thursday. The company has a market capitalization of $2.07 billion, a PE ratio of -10.39 and a beta of -2.46. Pharvaris has a 52-week low of $20.65 and a 52-week high of $43.25. The business's fifty day moving average is $34.91 and its 200 day moving average is $32.29.

Pharvaris (NASDAQ:PHVS - Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06).

Insider Buying and Selling at Pharvaris

In other news, President Peng Lu sold 100,000 shares of the company's stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $35.00, for a total value of $3,500,000.00. Following the completion of the sale, the president owned 64,953 shares of the company's stock, valued at approximately $2,273,355. This represents a 60.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Johannes Gerardus Chri Schikan sold 200,000 shares of the stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $35.00, for a total transaction of $7,000,000.00. Following the transaction, the director directly owned 115,167 shares in the company, valued at approximately $4,030,845. This represents a 63.46% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 513,102 shares of company stock valued at $18,643,666. 11.84% of the stock is currently owned by corporate insiders.

Institutional Trading of Pharvaris

Several hedge funds have recently added to or reduced their stakes in PHVS. Quantbot Technologies LP bought a new position in shares of Pharvaris during the second quarter valued at about $41,000. CoreCap Advisors LLC purchased a new stake in Pharvaris during the 2nd quarter valued at about $93,000. Public Employees Retirement System of Ohio purchased a new stake in Pharvaris during the 2nd quarter valued at about $196,000. Algert Global LLC bought a new position in Pharvaris during the 2nd quarter worth approximately $238,000. Finally, Persistent Asset Partners Ltd bought a new position in Pharvaris during the 2nd quarter worth approximately $273,000.

About Pharvaris

Pharvaris N.V. NASDAQ: PHVS is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE) and other diseases associated with bradykinin-mediated swelling. HAE is a rare genetic disorder that can cause recurring, potentially life-threatening attacks affecting areas such as the skin, gastrointestinal tract and airways.

The company's lead program is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist formerly known as PHA121.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.